In Vitro Regulation of Th1/Th2 Cell of PBMCs in AR Mice by si-GATA-3
-
摘要:
目的 研究RNAi介导的GATA-3基因慢病毒载体si-GATA-3在体外对变应性鼻炎(allergic rhinitis,AR)小鼠PBMCs中Th2、Th1细胞亚群功能的调节作用。 方法 构建RNAi介导的GATA-3基因慢病毒载体si-GATA-3,并进行包装、纯化和滴定。BALB/C小鼠随机分为AR组和正常对照组。用卵蛋白构建BALB/C小鼠变应性鼻炎模型,抽取其外周血并分离外周血中单个核细胞(PBMCs),随机分为3组,即si-GATA-3组、si-NC组和AR 组。进行细胞培养,然后分别用si-GATA-3、si-NC和生理盐水对3组变应性鼻炎小鼠的PBMCs进行干预72 h,用生理盐水代替si-GATA-3干预正常对照组小鼠的PBMCs。干预结束分离PBMCs和细胞培养上清液。分别用荧光定量qPCR和Western bloting方法检测PBMCs中GATA-3 mRNA、T-bet mRNA和GATA-3 、T-bet蛋白的相对表达量;用ELISA技术检测细胞培养上清液中IL-4和IFN-γ的含量。 结果 构建出RNAi介导的GATA-3基因慢病毒载体si-GATA-3,其滴度为5×108 TU/mL。制备出BALB/C小鼠的AR模型。Si-GATA-3组PBMCs中GATA-3 mRNA、GATA-3蛋白的相对表达量和上清液中IL-4的含量均明显低于AR组和si-NC组的表达量(P < 0.01),AR组和si-NC组中3者的表达量均明显高于正常对照组( P < 0.01);AR组3者表达量和si-NC组无差异( P > 0.05)。si-GATA-3组PBMCs中T-bet mRNA及其蛋白的相对表达量明显高于AR组和si-NC组的表达量( P < 0.01),AR组和si-NC组中二者的表达量均明显低于对照组( P < 0.01);AR组的二者表达量和si-NC组无差异( P > 0.05)。但si-GATA-3组细胞培养上清液中IFN-γ的含量高于正常对照组( P < 0.05),AR组与si-NC组中IFN-γ明显高于正常对照组和si-GATA-3组( P < 0.01);AR组与si-NC组之间IFN-γ的表达,差异无统计学意义( P > 0.05)。 结论 si-GATA-3能有效的下调Th2细胞中GATA-3 mRNA、GATA-3蛋白和IL-4的表达,并上调Th1细胞中T-bet mRNA和T-bet蛋白的表达,体外能有效地纠正小鼠AR模型中PBMCs中Th2/Th1的免疫失衡。 Abstract:Objective To investigate regulatory effect of the Lentivirus-mediated-GATA-3 RNAi (si-GATA-3)on the Th1/Th2 imbalance in a murine model of allergic rhinitis in vitro. Methods The lentiviral vector SI-GATA-3 with GATA-3 gene mediated by RNAi was developed and packaged, purified and titrated. BALB/C mice were randomly divided into AR group and normal control group. The allergic rhinitis model of BALB/C mice was developed by using ovalbumin (OVA). The peripheral blood of BALB/C mice was collected and their mononuclear cells (PBMCs) were isolated. The PBMCs were randomly divided into three groups, namely, si-GATA-3 group, si-NC group and AR group. si-GATA-3, si-NC and normal saline were used to intervene PBMCs in allergic rhinitis mice for 72 h, and normal saline was used to replace si-GATA-3 to intervene PBMCs in normal control mice. PBMCs and cell culture supernatant were separated after the intervention. The relative expression levels of GATA-3 mRNA, T-bet mRNA and GATA-3, T-bet protein in PBMCs were detected by fluorescence quantitative qPCR and Western bloting, respectively. The contents of IL-4 and IFN-γ in supernatant of cell culture were determined by ELISA. Results The RNAi mediated lentiviral vector si-GATA-3 with a titer of 5×108 TU/mL was successfully deeloped. The allergic rhinitis mice models were established successfully. The relative expression levels of GATA-3 mRNA and GATA-3 protein and the content of IL-4 in supernatant of PBMCs in si-GATA-3 group were significantly lower than those in AR group and si-NC group (P < 0.01), and the expression levels of GATA-3 in AR group and si-NC group were significantly higher than those in normal control group ( P < 0.01). There was no difference between AR group and si-NC group ( P > 0.05). The relative expression of T-bet mRNA and T-bet protein in si-GATA-3 group was significantly higher than that in AR group and si-NC group ( P < 0.01), and the expression of T-bet mRNA and T-bet protein in AR group and si-NC group was significantly lower than that in control group ( P < 0.01). There was no difference between AR group and si-NC group ( P > 0.05). However, the content of IFN-γ in cell culture supernatant of si-GATA-3 group was higher than that of normal control group ( P < 0.05), and the content of IFN-γ in AR and si-NC groups was significantly higher than that of normal control group and si-GATA-3 group ( P < 0.01). There was no significant difference in IFN-γ expression between AR group and si-NC group ( P > 0.05). Conclusions si-GATA-3 could down-regulate the relative expression of GATA-3 mRNA , GATA-3 protein and IL-4 level in Th2 cells, and up-regulate the relative expression of T-bet mRNA and T-bet protein in Th1 cells. Therefor, it can effectively correct the immune imbalance of Th2/Th1 in PBMCs in mouse AR model. -
Key words:
- Rhinitis /
- Allergic /
- RNA interference /
- GATA-3 /
- T-bet /
- Lentiviral vector /
- Model /
- Mouse
-
随着微创介入血管内技术的不断发展与改进,微创介入血管内手术已在全国各地广泛开展。但手术过程中导丝、导管、球囊、支架、弹簧圈等医源性材料的折断、解旋并留置于血管内的情况时有发生[1-3],这些医源性材料留置于人体血管内即成为血管内异物(Intravascular foreign bodies ),其可导致血栓形成、血管闭塞、血管穿透、心率失常等事件的发生甚至可危及患者生命[4-5]。虽然目前有血管内异物取出的术式,但因血管内异物留置部位的不同,或术者操作技术和经验积累的差异,血管内异物取出的成功率并不高。此外,血管异物取出的操作风险较高,一旦发生此类异物留置于血管内的事件,患者不仅处于较高的医疗风险下,术者也将承受巨大的心理压力,同时也增加了相关医疗纠纷发生的可能。医源性异物留置于血管内事件发生后,术者应尽可能地将异物取出,这要求术者有丰富的操作经验和合适的异物抓捕器械。因此,在现有血管内异物抓捕器械的基础上,笔者介绍一种自制异物抓捕器,该自制异物抓捕器的研制有着十分重要的临床意义和应用价值。
1. 资料与方法
1.1 研究对象
在模拟人体内血管的体外血管模型(简称模拟人)(见图1A)上构建由废弃导丝、废弃导管、废弃支架、废弃弹簧圈存留于模拟人股动脉、髂内动脉、髂总动脉、腹主动脉、胸主动脉、主动脉弓、无名动脉、颈总动脉、颈内动脉、椎动脉等不同血管部位的异物存留模型,该模型作为本试验研究对象。试验研究器械为自制抓捕器和传统异物抓捕器,后者包括临床中使用相同规格的活检钳、异物钳及血管内异物抓捕器如环状圈套抓捕器、篮网状抓捕器、三角爪型抓捕器。本自制异物抓捕器由头端抓钳、体部导管和尾部固定握把三部分组成,头端为小型金属抓钳,可直接对异物进行抓取。体部为软质塑料制成的中空导管,在对抓钳提供必要支撑力的同时可顺应血管形状到达血管内不同位置,该管状结构内腔可通过微导丝或泥鳅导丝引导头端抓钳至异物留置处,体部导管和固定握把间有一通道相通,也可将折叠导丝经固定握把处的通道置入,通过抓捕器体部导管的内腔出头端行成环状圈套对异物进行圈套,抓捕器头端抓钳和体部导管可整体通过8F导引导管。固定握把由硬质塑料制成,形态与金属活检钳握把类似(见图1B)。
1.2 实验方法
将模拟人以仰卧位置于试验操作台上,模拟全身麻醉状态下,双侧腹股沟区消毒并常规铺巾。于右侧腹股沟区行股动脉穿刺,置入8F动脉鞘,在X线动脉透视下,泥鳅导丝引导8F导引导管(Envoy,美国强生公司)沿动脉鞘置入模拟人血管内。将废弃导丝、废弃导管、废弃支架、废弃弹簧圈由近及远置于模拟人股动脉、髂内动脉、髂总动脉、腹主动脉、胸主动脉、主动脉弓、无名动脉、颈总动脉、颈内动脉、椎动脉等做成不同异物存留不同部位的异物存留模型。留置于股动脉、髂内动脉的异物以8F动脉鞘为通道,在动态透视下分别用自制抓捕器和活检钳、异物钳、血管内异物抓捕器进行异物抓取。对于留置其它动脉的异物,泥鳅导丝引导8F指引导管到达异物近端,将自制抓捕器和活检钳、异物钳、血管内异物抓捕器置入8F指引导管内,动态透视下抓取异物。活检钳、异物钳、血管内异物抓捕器根据其器械长度在其可应用范围内进行模拟人血管内异物抓取。自制抓捕器和活检钳、异物钳、血管内异物抓捕器钳住或圈套住异物后,将异物沿8F导引导管和8F动脉鞘内抓取出模拟人体外。
1.3 记录方法
将应用自制抓捕器进行模拟人血管内异物的抓取记录为自制抓捕器组,将应用活检钳、异物钳和血管内异物抓捕器进行模拟人血管内异物的抓取记录为传统抓捕器组。用自制抓捕器或活检钳、异物钳、血管内异物抓捕器钳住或圈套住异物成功后,将异物沿8F导引导管和8F动脉鞘内抓取出模拟人体外视为本次抓取成功,否则视为本次抓取失败。每组各进行80次模拟人血管内异物抓取,两组共计160次。
1.4 评估方法
(1)比较自制抓捕器组与传统抓捕器组的1次取出异物成功率;(2)比较自制抓捕器组与传统抓捕器组的3次内取出异物成功率;(3)比较自制抓捕器组与传统抓捕器组的取出异物总体成功率;(4)记录并比较自制抓捕器组与传统抓捕器组取出每例异物的平均操作时间。
1.5 统计学方法
所有数据采用SPSS 22.0统计学软件进行处理,计数资料用百分率(%)表示,计量资料用均数±标准差(
$\bar x \pm s $ )表示。各组数据间采用Pearson χ2检验或Student’ t检验,所有分析结果以P < 0.05为差异有统计学意义。2. 结果
2.1 自制抓捕器组与传统抓捕器组抓取异物的1次取出异物成功率、3次内取出异物成功率、取出异物总体成功率比较
自制抓捕器组和传统抓捕器组1次取出异物分别为58例和42例,两组有统计学差异(χ2 = 6.827,P = 0.009);自制抓捕器组3次内取出异物分别为58例、15例和4例,传统抓捕器组3次内取出异物分别为42例、14例和14例,两组有统计学差异(χ2 = 7.834,P = 0.020);自制抓捕器组和传统抓捕器组3次内取出异物分别为77例和70例,两组有统计学差异(χ2 = 4.103,P = 0.043),见表1 。
表 1 自制抓捕器组与传统抓捕器组取出异物的例数[n(%)]Table 1. The number of cases of retrieving foreign bodies between the self-made retrieval device group and the traditional retrieval device group[n(%)]组别 自制抓捕器组 传统抓捕器组 操作次数(次) 80 80 第1次取出异物 58(72.5) 42(52.5)* 第2次取出异物 15(18.8) 14(17.5)* 第3次取出异物 4(5.0) 14(17.5)* 成功取出异物 77(96.3) 70(87.5)* 与自制抓捕器组比较,*P < 0.05。 2.2 自制抓捕器组与传统抓捕器组取出每例异物的平均操作时间比较
自制抓捕器组取出异物77例的每例异物的平均操作时间为(7.42±1.68)min,显著短于传统抓捕器组70例的(13.21±5.25)min,两组有统计学差异(t = 9.192,P = 0.000),见表2。
表 2 自制抓捕器组与传统抓捕器组取出每例异物的平均操作时间[($\bar x\pm s $ ),min]Table 2. The average time for retrieving each foreign body between the self-made retrieval device group and the traditional retrieval device group[($\bar x\pm s $ ),min]组别 自制抓捕器组 传统抓捕器组 操作次数(次) 80 80 取出每例异物平均时间 7.42 ± 1.68 13.21 ± 5.25* 与自制抓捕器组比较,*P < 0.05。 3. 讨论
在微创介入血管内手术中,虽然医源性器械异物脱落后留置于患者血管内的事件并不常见,但该类事件一旦发生却是手术中非常严重的并发症[4],常由于器械本身质量不佳或术者手术操作失误而引起[1,6],且一定程度上属于医疗事故,血管内异物留置可存在于动脉或静脉内,文献报道[7]约80%的血管内异物存留于动脉,约80% 的患者有缺血症状,约20%异物存留于静脉,约30%患者有呼吸困难、咯血、胸痛等症状。留置于血管内的异物可造成血栓形成从而闭塞血管。异物随血流漂浮可栓塞动脉,导致脑梗死、肺梗死、心肌梗死、肾梗死、脾梗死等。部分异物可随血流搏动将周围的血管壁刺破造成出血。异物留置于血管内还可形成有菌性炎症或无菌性炎症,严重情况下导致菌血症甚至可危及患者生命[1]。因此对于医源性脱落于血管内的器械异物,若其能在X线下显影,以及在血管内异物抓捕器械使用范围内及术者操作能力允许,术者均应尽可能取出[2,6]。反之则应密切观察患者术后各项生命体征及神经功能,及时给予对症处理,并定期复查血管内异物的情况。
血管内医源性脱落异物取出的手术方式包括外科血管切开异物取出术与微创介入血管内异物取出术两种。以往对血管内异物的处理方法是行外科手术血管切开异物取出[6],但这种术式属于开放性手术,对患者创伤较大,且需直接切开血管,大量出血及感染等风险较高。医源性血管内异物一般为断裂导丝、断裂导管、释放支架、解旋弹簧圈等,这些异物可随心跳搏动和呼吸运动而在血管内漂流移动,存在术前定位后异物再移位的问题[2,8],进一步增加异物取出的难度甚至或可因异物再移位而导致手术失败。目前临床应用较多的是微创介入的术式行血管内异物取出,其显著优势在于对患者的创伤极小,安全性较以往的外科血管切开异物取出术明显提高。此外,在动态X线透视下,可实现对血管内异物位置的实时监测,大大提高异物定位的准确性和异物取出成功率[9-12],因此在临床中作为首选的血管异物取出的术式,外科血管切开异物取出术仅在血管内术式取出失败[2,6]以及必须行异物取出时才考虑运用。
临床上常用的异物抓取器械多为活检钳或异物钳,如硬质活检钳、软质活检钳、内镜内活检钳等,其头端有多种形状以用于不同部位,常应用于呼吸道、消化道和腹腔内等肉眼能够直视或借助内窥镜等手段观察到的部位[13-14]。活检钳和异物钳的固定握把形态能良好契合人体手指、手掌活动功能,使术者在手术中的操作较为方便灵活,但因其钳体常较短且坚硬,极少运用于血管内的异物取出,仅在紧急情况下可尝试使用[15]。血管内环状圈套抓捕器、篮网状抓捕器、三角爪型抓捕器为目前临床上常用的血管内异物抓捕器械[1,4,16],但因其头端圈套装置设计单一,对异物的抓持力较弱,抓取能力有限。对一些嵌顿较为稳固或留置位置不易到达的异物取出较为困难,且部分抓捕器本身材质偏硬,头端尖锐,易损伤血管内膜或穿破血管。大部分血管内异物抓捕器通过旋转抓捕器近端的扭控器来实现对抓捕器头端圈套的控制从而抓捕异物,但缺点在于通过扭控器传导的旋转或推拉力量仅部分能传达至抓捕器头端,因此术者难以高效掌控抓捕器对异物的抓取。此外,术者对扭控器的操作相比较于较活检钳或异物钳固定握把的操作更为不便,无形中增加了血管内异物取出的时间。因此,在结合活检钳或异物钳和血管内抓捕器两者原基础上对其结构和材料进行改造,设计出一种包含抓钳和圈套形头端的自制异物抓捕器,使其能在血管内安全、有效、操作便捷地使用,旨在高效地取出血管异物,降低手术风险。
本自制抓捕器头端为抓钳与圈套双重设计,抓钳能对异物的抓取提供强大的抓持力,易于将嵌顿较为牢固的血管内异物如断裂导丝、断裂导管、释放支架、解旋弹簧圈等异物取出,头端的圈套也可以辅助抓钳进行圈套异物,进一步提高异物的取出效率。抓钳头端可通过旋转抓捕器的固定把手自由旋转,方便用于抓取留置于血管内不同位置、不同角度的异物,可将操作时间明显缩短。该自制抓捕器中间段为导管状结构,管体质地较为柔软顺滑,可轻松通过抓钳外层的导引导管通路,在血管内也能够较少对血管的造成损伤。本自制抓捕器在传统活检钳、异物钳的基础上进行了延长设计,经股动脉穿刺沿导引导管置入后可到达右侧颈内动脉高度,扩大了异物取出的范围。且抓捕器固定握把与活检钳或异物钳相类似,较传统血管内异物抓捕器更便于术者的操作使用。
本试验研究采用自制异物抓捕器与传统异物抓捕器在模拟人血管内各进行80次异物抓取并比较两组抓取异物的效果。结果显示自制抓捕器组较传统抓捕器组有更高的1次取出异物成功率、3次内取出异物成功率、取出异物总体成功率和更短的取出每例异物平均操作时间,差异均有统计学意义(P < 0.05)。这说明本自制异物抓捕器较传统异物抓捕器能更有效地实施血管内异物取出。其有效性在本次试验中已得到初步验证。但该试验总共抓取次数仅为160次,为小样本量试验,仍需进一步完善更大样本量的试验。综上所述,在模拟人血管内操作,本自制异物抓捕器较传统异物抓捕器能更有效地抓取模拟人血管内异物,成功率更高,操作时间更短。
-
表 1 AR小鼠症状评分标准
Table 1. Symptom scoring criteria for AR mice
分级积分 喷嚏(个) 鼻分泌物量 挠鼻次数 0 0 无 无 1 1~3 前鼻孔有鼻分泌物 轻微挠鼻几次 2 4~10 鼻分泌物超过前鼻孔 双爪反复挠鼻 3 > 11 面部布满鼻分泌物 挠鼻面部不止,四处摩擦 表 2 GATA-3和T-bet mRNA引物
Table 2. The primer of GATA-3 and T-bet mRNA
引物 序列 大小 GATA-3 mRNA F:CCACGGGAGCCAGGTATG 169 bp R:CGGAGGGTAAACGGACAGAG T-bet mRNA F:GGACCCAACTGTCAACTGC 490 bp R:TGTCGCCACTGGAAGGAT β-actin mRNA F:GAGACCTTCAACACCCCAGC 263 bp R:ATGTCACGCACGATTTCCC -
[1] Bousquet J,Anto J M,Bachert C,et al. Allergic rhinitis[J]. Nat Rev Dis Primers,2020,6(1):95. doi: 10.1038/s41572-020-00227-0 [2] Pallasaho P,Juusela M,Lindqvist A,et al. Allergic rhinoconjunctivitis doubles the risk for incident asthma-results from a population study in Helsinki,Finland[J]. Respir Med,2011,105(10):1449-1456. doi: 10.1016/j.rmed.2011.04.013 [3] Brozek J L,Bousquet J,Baena Cagnani C E,et al. Allergic rhinitis and ita impact on asthma (ARIA) guidelines:2010 revision[J]. J Allergic Clin Immunol,2010,126(3):466-476. doi: 10.1016/j.jaci.2010.06.047 [4] Wang X D,Zheng M,Lou H F,et al. An increased prevalence of self-reported allergic rhinitis in major chineae cities from 2005 to 2011[J]. Allergy,2016,71(8):1170-1180. doi: 10.1111/all.12874 [5] 刘阳,刘争. Ⅱ型固有淋巴细胞作用、调节及在慢性上呼吸道炎性疾病中的研究[J]. 中华耳鼻咽喉头颈外科杂志,2017,52(2):130-135. doi: 10.3760/cma.j.issn.1673-0860.2017.02.017 [6] Yao Y,Wang Z C,Wang N,et al. Allergen immunotherapy improves defective follicular T cells in patiens with allergic rhintis[J]. J Allergy Clin Immunol,2019,144(1):118-128. doi: 10.1016/j.jaci.2019.02.008 [7] Yao Y,Chen C L,Wang N,et al. Correlation of allergen-specific T follicular helper cell counts with specific IgE levels and efficacy of allergen immunotherapy[J]. J Allergy Clin Immunol,2018,142(1):321-324. doi: 10.1016/j.jaci.2018.03.008 [8] Jutel M,Akdis C A. T-cell subset regulation in atopy[J]. Curr Allergy Asthma Rep,2011,11(2):139-145. doi: 10.1007/s11882-011-0178-7 [9] Yagi R,Zhu J,Paul W E. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation[J]. Int Immunol,2011,23(7):415-420. doi: 10.1093/intimm/dxr029 [10] Naito T,Tanaka H,Naoe Y,et al. Transcriptional control of T-cell development[J]. Int Immunol,2011,23(11):661-668. doi: 10.1093/intimm/dxr078 [11] Finotto S,Neurath M F,Glickman J N,et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet[J]. Science,2002,295(5553):336-338. doi: 10.1126/science.1065544 [12] Zeng W P. All things considered':Transcriptional regulation of T helper type 2 cell differentiation from precursor to effector activation[J]. Immunology,2013,140(1):31-38. doi: 10.1111/imm.12121 [13] 陈冬,李玉晓,李添应,等. 大蒜新素对变应性鼻炎大鼠转录因子T-bet和GATA-3表达的影响[J]. 中华耳鼻咽喉头颈外科杂志,2010,45(2):133-138. doi: 10.3760/cma.j.issn.1673-0860.2010.02.011 [14] Son H L,Park H R,Park Y J,et al. Effect of retinoic acid in a mouse model of allergic rhinitis[J]. Allergy Asthma Immunol Res,2015,7(6):590-598. doi: 10.4168/aair.2015.7.6.590 [15] Zhang Y,Feng J,Sun J,et al. H2-Eb1 expression is upregulated in the nasal mucosa of allergic rhinitis[J]. Asian Pac J Allergy Immunol,2014,32(4):308-315. [16] Laurent S,Boutry S,Mahieu I,et al. Iron oxide based MR contrast agents:From chemistry to cell labeling[J]. Curr Med Chem,2009,16(35):4712-4727. doi: 10.2174/092986709789878256 [17] 李玉晓,何晓光,姚永刚,等. 小鼠GATA-3基因RNA干扰慢病毒载体的构建与鉴别[J]. 临床耳鼻咽喉头颈外科杂志,2017,38(8):627-632. doi: 10.13201/j.issn.1001-1781.2017.08.014 [18] 李林格,冯娟,胡斌,等. 实验变应性鼻炎模型小鼠构建以及与Th1/Th2失衡的相关性[J]. 中国组织工程研究,2015,19(40):6515-6519. doi: 10.3969/j.issn.2095-4344.2015.40.022 [19] Raby B A,Hwang E S,Van Steen K,et al. T-bet polymorphisms are associated with asthma and airway hyperresponsiveness[J]. Am J Respir Crit Care Med,2006,173(1):64-70. doi: 10.1164/rccm.200503-505OC [20] Zhu J,Yamane H,Cote-Sierra J,et al. GATA-3 promotes Th2 responses through three different mechanisms:Induction of Th2 cytokine production,selective growth of Th2 cells and inhibition of Th1 cell-specific factors[J]. Cell Res,2006,16(1):3-10. doi: 10.1038/sj.cr.7310002 [21] Malmhall C,Bossios A,Pullerits T,et al. Effects of pollen and nasal glucocorticoid on FOXP3+,GATA-3+ and T-bet+ cells in allergic rhinitis[J]. Allergy,2007,62(9):1007-1013. doi: 10.1111/j.1398-9995.2007.01420.x [22] Finotto S,De Sanctis G T,Lehr HA,et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression[J]. J EXP Med,2001,193(11):1247-1260. doi: 10.1084/jem.193.11.1247 [23] Huang H Y,Lee C C,Chiang B L,et al. Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyperresponsiveness[J]. Gene Therapy,2008,15(9):660-667. doi: 10.1038/gt.2008.15 [24] Holgate S T,Polosa R. Treatment strategies for allergy and asthma[J]. Nat Rev Immunol,2008,8(3):218-230. doi: 10.1038/nri2262 [25] Behera A K, Kumar M, Lockey R F, et al. Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin12 and STAT4 signaling[J].Hum Gene Ther, 2002, 13(14): 1697-1709. [26] Yanyun Luo,Yuqin Deng,Zezhang Tao,et al. Regulatory effect of microRNA-135a on the Th1/Th2 imbalance in a murine model of allergic rhinitis[J]. Experimental and Therapeutic Medicin,2014,8(4):1105-1110. doi: 10.3892/etm.2014.1855 [27] Zhu X Y,Wang X P,W ang Y,et al. The regulatory network among CircHIPK3,LncGAS5,and miR-495 promotes Th2 differentiation in allergic rhinitis[J]. Cell Death Dis,2020,11(4):216-228. doi: 10.1038/s41419-020-2394-3 [28] Koh D M,Brown G,Collins D J. Nanoparticles in rectal cancer imaging[J]. Cancer Biomark,2009,5(2):89-98. doi: 10.3233/CBM-2009-0544 期刊类型引用(8)
1. 胡焓,罗欢. 超声引导下0.5%罗哌卡因股神经阻滞镇痛在髌骨骨折切开复位内固定术中的应用效果. 现代诊断与治疗. 2024(03): 374-376 . 百度学术
2. 傅从良,冯伊文. 超声引导下股神经阻滞在髌骨骨折患者术后镇痛中的应用效果. 世界复合医学(中英文). 2024(08): 137-140 . 百度学术
3. 祁恩耀,许娟,龚睿,张云辉,王鹏. 右美托咪定复合罗哌卡因收肌管阻滞在胫骨折患者术前超前镇痛中的应用. 系统医学. 2024(19): 64-67 . 百度学术
4. 叶映芬,李昆伦,陈伟元,赖尚导. 右美托咪定在骨科手术麻醉与镇痛中的应用进展. 药学前沿. 2024(12): 711-718 . 百度学术
5. 李娟,杨璐,汤娜娜,曹福羊. 近端联合远端收肌管阻滞在全膝关节置换术患者术后镇痛和早期功能康复中的应用. 安徽医学. 2023(01): 68-73 . 百度学术
6. 杨云丽,李娜,邱昌明,普俊杰,聂维,李治贵. 超声引导下前路腰方肌阻滞对髋关节手术患儿术后镇痛效果. 昆明医科大学学报. 2023(04): 88-92 . 本站查看
7. 董红坤,王朝君,孟醒. 联合激光疗法对髌骨骨折术后患者炎症吸收水平、膝关节功能康复的影响. 江苏卫生保健. 2023(03): 175-177 . 百度学术
8. 于天雷,刘颖,张兰. 右美托咪定复合0.2%罗哌卡因股神经阻滞对髌骨骨折的镇痛效果及神经递质的影响. 创伤外科杂志. 2023(09): 709-714 . 百度学术
其他类型引用(3)
-